Activation of lymphocytes, with the focus on subsets (CD8 T cells, NK cells and NKT cells) that are crucial in anti-tumor immune responses, was scored based on early-to-intermediate activation markers CD69, CD25, CD38 [55]. This evidence concerns the gene CD38 and neoplasm.